JACK BURTON
Osteopathic Medicine at Ocean Pkwy, Brooklyn, NY

6703488, Mar 9, 2004

Jan 15, 1999

09/231642

Jack D. Burton - Long Island City NY
David M. Goldenberg - Mendham NJ

Center for Molecular Medicine and Immunology - Belleville NJ

C07K 1600

53038885, 5303871, 4241301, 4241561

A method for intracellular delivery of drugs or other agents for diagnosis and therapy of malignancies or immune-mediated or inflammatory conditions. A targeting moiety of an antibody and the ligand-binding region of a selected cytokine receptor is used. The targeting moiety targets surface antigen on a specific cell population. The targeting moiety is administered to a subject, and then, after a specified interval, therapeutic or diagnostic agents linked to the cognate cytokine are given. The invention provides rapid, efficient internalization of the cytokine receptor antibody/antigen complexes. Targeting of a high-level cell surface antigen with such bispecific fusion molecules substantially increases the number of cytokine receptors over their low background level.

2004007, Apr 22, 2004

Nov 24, 2003

10/718534

Jack Burton - Long Island City NY, US
David Goldenberg - Mendham NJ, US

Center of Molecular Medicine and Immunology

C07K016/46, C07K014/715

530/391100, 530/350000

A method for intracellular delivery of drugs or other agents for diagnosis and therapy of malignancies or immune-mediated or inflammatory conditions. A targeting moiety of a an antibody and the ligand-binding region of a selected cytokine receptor is used. The targeting moiety targets surface antigen on a specific cell population. The targeting moiety is administered to a subject, and then, after a specified interval, therapeutic or diagnostic agents linked to the cognate cytokine then are given. The invention provides rapid, efficient internalization of the cytokine receptor antibody/antigen complexes. Targeting of a high-level cell surface antigen with such bispecific fusion molecules substantially increases the number of cytokine receptors over their low background level.

2006021, Sep 28, 2006

Mar 14, 2006

11/376598

Jack Burton - Long Island City NY, US
Rosalyn Blumenthal - West Orange NJ, US

A61K 31/44, A61K 31/165

514352000, 514619000

The present invention relates to compositions and methods of using peroxisome proliferator-activated receptor-gamma (PPARγ) antagonists. In one embodiment, the present invention relates to compositions and methods for preparing and using such antagonist compositions. In another embodiment, the present invention provides for using PPAR-gamma antagonist compositions to treat disease such as cancer. In other embodiments, the present invention provides for using PPAR-gamma antagonist and one or more additional anti-cancer agent compositions to treat cancer.

2011017, Jul 14, 2011

Jan 11, 2011

13/004349

Jack D. Burton - Long Island City NY, US
Rhona Stein - Maplewood NJ, US
David M. Goldenberg - Mendham NJ, US

CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY - Belleville NJ
IMMUNOMEDICS, INC. - Morris Plains NJ

A61K 38/20, A61K 38/21, A61K 51/00, A61K 51/10, A61P 35/00, A61P 37/00

424 149, 424 855, 424 111, 424 852

Disclosed herein are methods and compositions comprising interferon-γ (IFN-γ) and anti-CD74 or anti-HLA-DR antibodies. In preferred embodiments, the IFN-γ increases the expression of CD74 and/or HLA-DR in target cells and increases the sensitivity of the cells to the cytotoxic effects of the anti-CD74 or anti-HLA-DR antibodies. The compositions and methods are of use to treat diseases involving CD74 and/or HLA-DR cells, such as cancer cells, autoimmune disease cells or immune dysfunction disease cells.

2012032, Dec 20, 2012

Aug 6, 2012

13/567226

Jack D. Burton - Long Island City NY, US
Rhona Stein - Maplewood NJ, US
David M. Goldenberg - Mendham NJ, US

IMMUNOMEDICS, INC. - Morris Plains NJ
CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY - Morris Plains NJ

A61K 39/395, A61P 35/02, A61P 37/00, A61P 37/06, A61K 38/20, A61P 19/02, A61P 1/04, A61P 1/16, A61K 51/10, A61K 38/19, A61P 35/00, A61P 3/10

424 149, 4241721, 4241741, 4241331, 4241781, 4241361, 424 851, 424 852, 4241351

Disclosed herein are methods and compositions comprising interferon-γ (IFN-γ) and anti-CD74 or anti-HLA-DR antibodies. In preferred embodiments, the IFN-γ increases the expression of CD74 and/or HLA-DR in target cells and increases the sensitivity of the cells to the cytotoxic effects of the anti-CD74 or anti-HLA-DR antibodies. The compositions and methods are of use to treat diseases involving CD74 and/or HLA-DR cells, such as cancer cells, autoimmune disease cells or immune dysfunction disease cells.